Moteur de recherche d’entreprises européennes
Financement de l’UE (3 577 313 €) : Plate-forme BIOsensing ultrasensible pour le phénotypage multiplex des protéines CELLulaires au niveau d’une seule cellule Hor28/01/2021 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Plate-forme BIOsensing ultrasensible pour le phénotypage multiplex des protéines CELLulaires au niveau d’une seule cellule
BIOCELLPHE provides frontier scientific and technological advancements to generate a breakthrough technology realizing the identification of proteins (i.e. phenotyping) as diagnostic biomarkers at single-cell level with unmatched sensitivity, multiplexing capabilities and portability. BIOCELLPHE proposes the generation of engineered bacteria able to recognize and bind to specific protein targets on the surface of circulating tumor cells (CTCs) responsible for cancer metastasis, thereby triggering the production of chemical signals that can be detected simultaneously, and with extremely high sensitivity by surface-enhanced Raman scattering (SERS). SERS is a powerful analytical technique that employs plasmonic nanoparticles as optical enhancers for ultrasensitive chemical analysis achieving single-molecule detection level. BIOCELLPHE will implement these advancements toward the generation of an optofluidic lab-on-a-chip SERS device enabling ultrasensitive identification and multiplex phenotyping of CTCs. We anticipate that BIOCELLPHE long-term vision and scientific breakthrough will lead to a sky limit technology that will be widely applicable, not only in the diagnostic arena, but also in many other applications (e.g. biomedical, environmental). No one has previously been able to attempt this vision due to current challenges and technical limitations, but we believe to be in a position to pave a way for achieving this now. To realize this highly ambitious project, BIOCELLPHE gathers a highly multidisciplinary community of leading experts in synthetic biology, nanotechnology, plasmonics, microfluidics, artificial intelligence, and cancer diagnosis. We believe that successful deployment of BIOCELLPHE has the potential to usher in a new era of medical diagnostics and it will provide new paradigms in biology and biomedicine, advancing frontier science and technologies at the European academic and industrial sectors.
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | 534 188 € |
| Institut National de la Sante et de la Recherche Medicale | 530 375 € |
| Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement | 531 875 € |
| International Iberian Nanotechnology Laboratory | 448 125 € |
| Istituti Clinici Scientifici Maugeri S.p.A. Societa' Benefit | 155 625 € |
| Rubynanomed Lda. | 150 000 € |
| Tematys | 215 875 € |
| Universidad de Vigo | 708 000 € |
| Universidad Politecnica de Madrid | 303 250 € |
https://cordis.europa.eu/project/id/965018
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
